Logo image of ISRL

ISRAEL ACQUISITIONS CORP-A (ISRL) Stock Fundamental Analysis

USA - NASDAQ:ISRL - KYG496671010 - Common Stock

13 USD
+0.35 (+2.77%)
Last: 9/25/2025, 8:00:02 PM
12.38 USD
-0.62 (-4.77%)
After Hours: 9/4/2025, 8:15:02 PM
Fundamental Rating

1

Overall ISRL gets a fundamental rating of 1 out of 10. We evaluated ISRL against 0 industry peers in the Unkown industry. The financial health of ISRL is average, but there are quite some concerns on its profitability. ISRL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ISRL had positive earnings in the past year.
In the past year ISRL had a positive cash flow from operations.
ISRL Yearly Net Income VS EBIT VS OCF VS FCFISRL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 2M 4M 6M

1.2 Ratios

Industry RankSector Rank
ROA 13.8%
ROE 65.28%
ROIC N/A
ROA(3y)-1.16%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ISRL Yearly ROA, ROE, ROICISRL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

ISRL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ISRL Yearly Profit, Operating, Gross MarginsISRL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, ISRL has less shares outstanding
Compared to 1 year ago, ISRL has a worse debt to assets ratio.
ISRL Yearly Shares OutstandingISRL Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M 25M
ISRL Yearly Total Debt VS Total AssetsISRL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

ISRL has an Altman-Z score of 5.47. This indicates that ISRL is financially healthy and has little risk of bankruptcy at the moment.
ISRL has a debt to FCF ratio of 1.02. This is a very positive value and a sign of high solvency as it would only need 1.02 years to pay back of all of its debts.
A Debt/Equity ratio of 0.76 indicates that ISRL is somewhat dependend on debt financing.
Although ISRL does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.76
Debt/FCF 1.02
Altman-Z 5.47
ROIC/WACCN/A
WACCN/A
ISRL Yearly LT Debt VS Equity VS FCFISRL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 1.27 indicates that ISRL should not have too much problems paying its short term obligations.
A Quick Ratio of 1.27 indicates that ISRL should not have too much problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.27
Quick Ratio 1.27
ISRL Yearly Current Assets VS Current LiabilitesISRL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M

More info and screens

0

3. Growth

3.1 Past

ISRL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -67.78%.
EPS 1Y (TTM)-67.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-164.99%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 144.44, which means the current valuation is very expensive for ISRL.
Compared to an average S&P500 Price/Earnings ratio of 27.32, ISRL is valued quite expensively.
Industry RankSector Rank
PE 144.44
Fwd PE N/A
ISRL Price Earnings VS Forward Price EarningsISRL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF 54.07
EV/EBITDA N/A
ISRL Per share dataISRL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.1 0.2 0.3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ISRL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ISRAEL ACQUISITIONS CORP-A

NASDAQ:ISRL (9/25/2025, 8:00:02 PM)

After market: 12.38 -0.62 (-4.77%)

13

+0.35 (+2.77%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)08-14 2025-08-14
Earnings (Next)11-14 2025-11-14
Inst Owners42.01%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner Change0%
Market Cap82.55M
Analysts0
Price TargetN/A
Short Float %1.33%
Short Ratio1.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 144.44
Fwd PE N/A
P/S N/A
P/FCF 54.07
P/OCF 54.07
P/B 40.38
P/tB 40.38
EV/EBITDA N/A
EPS(TTM)0.09
EY0.69%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.24
FCFY1.85%
OCF(TTM)0.24
OCFY1.85%
SpS0
BVpS0.32
TBVpS0.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 13.8%
ROE 65.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-1.16%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.76
Debt/FCF 1.02
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 114.42%
Current Ratio 1.27
Quick Ratio 1.27
Altman-Z 5.47
F-Score8
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-67.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-164.99%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y8.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1022.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1022.03%
OCF growth 3YN/A
OCF growth 5YN/A